register free | resend password

Cognetivity Neurosciences Wins Prestigious AXA ‘Health Tech & You’ Award For Innovation in the Early Diagnosis of Dementia

ID: 1536061
recent pressrelease next pressrelease

(businesspress24) - Cognetivity Neurosciences Wins Prestigious AXA Health Tech & You Award For Innovation in the Early Diagnosis of Dementia

Vancouver, British Columbia, May 16, 2018 - Cognetivity Neurosciences Ltd. (the Company or Cognetivity) (CSE: CGN) (FWB:1UB) today announced that it has won the prestigious AXA Health Tech & You Challenge in the Innovations in the Early Diagnosis of Dementia category.

Created by AXA PPP Healthcare, part of the AXA Group, a worldwide leader in insurance and asset management with 165,000 employees serving 105 million clients in 64 countries, the Innovations in the Early Diagnosis of Dementia award was run in partnership with Alzheimers Research UK. It aimed to identify excellence in design innovation and technology development that could support the diagnosis of diseases underpinning dementia.

Submission came from an international field after a comprehensive pursuit for the most innovative new and emerging health tech. These were then shortlisted into just three technologies per category.

The winning Cognetivity platform involves a 5-minute Integrated Cognitive Assessment test (ICA) that looks for the earliest signs of impairment by testing the performance of large areas of the brain. The ICA is easy to administer and its Artificial Intelligence (AI) engine can learn as it gathers new data to improve its ability to diagnose. As well as having the potential to be a highly effective dementia screening tool, the ICA can also be used for remote monitoring of the progression of diseases and measuring the effectiveness of treatments.

Cognetivity CEO, Sina Habibi said, Were incredibly proud to have our technology recognized by AXA Health Tech & You and further validated by the judging panel who included hugely respected figures who are at the leading-edge of dementia research. We know there is an enormous unmet need globally for a tool able to provide early diagnosis of cognitive impairment and we believe we are well positioned to meet that demand. Dementia is a very significant and costly global problem, with 2018 Alzheimers Association figures stating that accurate early diagnosis could save up to 7.9 trillion dollars in medical and care costs in the US alone. Early diagnosis of the type we are working to bring to market can lead to drastically improved patient care and massively improved outcomes for sufferers as well as the financial benefits for payers. What is vital is that as many people as possible can benefit from the type of screening that our AI driven ICA platform could provide.

Dementia is the only condition in the top 10 causes of death without a treatment to prevent, cure or slow its progression. The early detection of dementia, in particular Alzheimers disease, is a critical unmet need in healthcare, with a recent Alzheimers Association report stating that the potential savings to healthcare of early and accurate dementia diagnosis could be as high as $7.9 trillion in the USA alone. Cognetivitys ICA platform technology is designed to detect some of the earliest signs of cognitive impairment, such as are present in dementia and other neurodegenerative disorders.

Today 50 million people have dementia globally, with 10 million additional cases being recorded annually. This equates to a new case being recorded every three seconds. Currently one out of two sufferers in higher income countries and nine out of 10 cases in lower income countries never receive a formal diagnosis.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivitys ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
For more information, please visit:

Sina Habibi

Sina Habibi
Chief Executive Officer and Director

For further information contact:
Email: info(at)

For media enquiries contact:
Josh Stanbury
Email: josh(at)


The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release.

More information:

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: irw
print pressrelease  send to a friend  

Date: 05/16/2018 - 15:29
Language: English
News-ID 1536061
Character count: 2296
Firma: Cognetivity Neurosciences Ltd.
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Wien


Number of hits: 551


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 004
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 73

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.